MYSTERIOUS: Dexcom - What They Never Told You

Beta Bionics Wins FDA Clearance for Mint Tubeless Insulin Patch Pump, Plans Pharmacy-Only U.S. Launch in Early 2027

The FDA cleared Beta Bionics' Mint tubeless insulin patch pump. What the clearance covers, when it launches, and what people with diabetes should know.

Medical Daily · Sep 16

A Second Company Joins the FDA Pilot That Lets Digital Devices Reach Medicare Patients Before Authorization

A blood pressure medication software system joined the FDA TEMPO pilot, a bigger clinical step than the first participant. Here is what changed.

Medical Daily · Aug 19

Is Wall Street Bullish or Bearish on DexCom Stock?

Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart · Aug 14

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

MarketBeat · Jun 20

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

MarketBeat · Jun 18

Is DexCom Stock Underperforming the Dow?

DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

Barchart · Jun 5

The DexCom Stock Turnaround Is Showing Real Signs of Life

DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is...

Barchart · May 20

DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day

DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase

MarketBeat · May 16

Are Wall Street Analysts Bullish on DexCom’s Stock?

Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects.

Barchart · May 15

Sell in May and Go Away—Starting With These 3 Stocks

Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.

MarketBeat · May 12